Cases
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
Merger
Overview
Overview
- Date:
- 10/16/2019
- Company Name:
- Achillion Pharmaceuticals, Inc.
- Stock Symbol:
- ACHN
- Company Name - Buyer:
- Alexion Pharmaceuticals, Inc.
- Status:
- Closed/Complete
- Merger Announcement Date:
- 10/16/2019
NEW YORK, October 16, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on behalf of Achillion shareholders concerning the proposed merger with Alexion Pharmaceuticals, Inc.
Pursuant to the proposed transaction, announced on October 16, 2019 and valued at $930 million, Achillion shareholders will receive $6.30 in cash for each share of Achillion common stock owned. Additionally, Achillion shareholders may receive non-tradeable contingent value rights (CVRs) upon the achievement of certain clinical and regulatory milestones. The investigation focuses on whether Achillion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Achillion shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Alexandra Raymond by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on October 16, 2019 and valued at $930 million, Achillion shareholders will receive $6.30 in cash for each share of Achillion common stock owned. Additionally, Achillion shareholders may receive non-tradeable contingent value rights (CVRs) upon the achievement of certain clinical and regulatory milestones. The investigation focuses on whether Achillion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Achillion shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Alexandra Raymond by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.